Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 3/20 | 0.40 |
| ▸ | CNR2 | P34972 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20359969 | 0.83 | CNR2 (0.40) | CNR2ALDH1A1KDM4EMAPT | |
| SCHEMBL20359968 | 0.83 | CNR2 (0.40) | CNR2ALDH1A1KDM4EMAPT | |
| SCHEMBL20359466 | 0.83 | CNR2 (0.56) | CNR2ALDH1A1KDM4EPOLBLMNA | |
| SCHEMBL20358961 | 0.83 | CNR2 (0.48) | CNR2ALDH1A1KDM4EPOLBNR3C1 | |
| SCHEMBL20359467 | 0.83 | CNR2 (0.56) | CNR2ALDH1A1KDM4EPOLBLMNA | |
| SCHEMBL20359070 | 0.83 | CNR2 (0.48) | CNR2ALDH1A1KDM4EPOLBNR3C1 | |
| SCHEMBL20360021 | 0.83 | CNR2 (0.40) | CNR2ALDH1A1KDM4ECYP2C19POLB | |
| SCHEMBL20358717 | 0.82 | MAPT (0.35) | ACACBCNR2MAPTCYP2C9CYP2C19 | |
| SCHEMBL20365221 | 0.81 | CNR2 (0.49) | CNR2 | |
| SCHEMBL20365245 | 0.81 | CNR2 (0.37) | CNR2ALDH1A1KDM4EMAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LCK | ACACB 2586/4885CNR2 1439/4885ALDH1A1 4650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.